HERCEPTIN
150mgHERCEPTIN150mg
HERCEPTIN (trastuzumab) 150mg is a targeted monoclonal antibody essential for treating HER2-positive breast cancer and gastric cancer, significantly improving survival outcomes.
Key Benefits
- Targeted therapy for HER2-positive cancers
- Significantly improves survival in breast cancer
- Both adjuvant and metastatic settings
- Well-established safety profile over 20+ years
- Weekly or 3-weekly dosing options
- Authentic Roche product with documentation
Contact Us for Pricing
Get competitive wholesale pricing for HERCEPTIN 150mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How HERCEPTIN Works
HERCEPTIN works through multiple mechanisms to target HER2-positive cancer cells:
1. **Receptor Blockade:** HERCEPTIN binds to the extracellular domain of HER2, preventing receptor dimerization and downstream signaling that promotes cancer cell proliferation and survival.
2. **Antibody-Dependent Cellular Cytotoxicity (ADCC):** The Fc portion of HERCEPTIN recruits natural killer (NK) cells and other immune effector cells to destroy HER2-positive cancer cells.
3. **Inhibition of HER2 Shedding:** HERCEPTIN prevents the cleavage of the HER2 extracellular domain, maintaining the full receptor on the cell surface where it can be targeted.
4. **Anti-Angiogenic Effects:** HERCEPTIN may inhibit angiogenesis (new blood vessel formation) that tumors need to grow.
The combination of direct anti-proliferative effects and immune activation makes HERCEPTIN a powerful targeted therapy for HER2-positive cancers.
About HERCEPTIN 150mg
HERCEPTIN (trastuzumab) 150mg and 440mg by Roche is a humanized monoclonal antibody that specifically targets the HER2 (human epidermal growth factor receptor 2) protein. This groundbreaking targeted therapy has transformed the treatment of HER2-positive breast cancer, which accounts for approximately 20-25% of all breast cancers and was historically associated with poor prognosis. By binding to the HER2 receptor, HERCEPTIN blocks signals that promote cancer cell growth and triggers antibody-dependent cellular cytotoxicity (ADCC), where immune cells are recruited to destroy cancer cells. HERCEPTIN has demonstrated significant improvements in survival when used in both early-stage (adjuvant) and metastatic HER2-positive breast cancer. HERCEPTIN is also approved for HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma in combination with chemotherapy. As a licensed pharmaceutical supplier, we provide authentic Roche HERCEPTIN with complete documentation, proper cold chain handling, and competitive wholesale pricing for healthcare providers worldwide.
Common Uses
- HER2-positive early breast cancer (adjuvant)
- HER2-positive metastatic breast cancer
- HER2-positive gastric/GEJ adenocarcinoma
- Combination with chemotherapy
- Maintenance therapy
Dosage Information
HERCEPTIN dosing depends on the indication and treatment setting:
Adjuvant Breast Cancer:
Metastatic Breast Cancer:
Metastatic Gastric Cancer (with chemotherapy):
Administer first infusion over 90 minutes with observation. If well tolerated, subsequent infusions may be given over 30 minutes.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store unopened HERCEPTIN vials under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake.
Reconstitution and Dilution:
For patients with benzyl alcohol hypersensitivity:
Protect from light during storage and administration.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About HERCEPTIN
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
